Krystal Biotech (KRYS) | Stock Overview & Key Data
Krystal Biotech Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $331.49 on June 12, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Krystal Biotech
KRYS
|
7.89B Mid-cap | 7.62% | 6.03% | 29.82% | 33.65% | 31.53% | 131.98% | 161.83% | 386.94% | 3,060.74% | 3,060.74% | 3,060.74% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | 7.77% | 11.28% | 60.15% | 73.28% | 41.81% | 145.12% | 200.20% | 278.87% | 3,924.76% | 2,713.34% | 2,713.34% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | 4.46% | -22.78% | -13.27% | -4.29% | -7.63% | 501.76% | 1,560.93% | -17.42% | -36.07% | -36.07% | -36.07% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 6.69% | 29.72% | 15.08% | -4.29% | -5.83% | 6.89% | -31.20% | -49.99% | 96.15% | 179.21% | 318.28% |
Ownership & Short Interest
Calculate Your Krystal Biotech Investment Returns
Long-Term Investment Performance Analysis
Krystal Biotech stock price in Sep 2017 was $10.06, A $1,000.00 lump sum investment in Krystal Biotech made 8 years ago would be worth approximately $32,281.31 today, representing a exceptional return of 3,128.13%. This translates to an annualized return (CAGR) of 48.82%.
8 Years 8 Months Investment Scenario (Sep 2017 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is KRYS's 52-week high and low?
- In the last 52 weeks, Krystal Biotech reached a high of $331.49 (on June 12, 2026) and a low of $127.99 (on June 18, 2025).
- What is the market cap and P/E ratio for KRYS?
- Curious about Krystal Biotech's size and valuation? Its market capitalization stands at 7.89B. When it comes to valuation, the P/E ratio (trailing twelve months) is 39.86, and the forward P/E (looking ahead) is 25.77.
- Does KRYS pay dividends? If so, what's the yield?
- As for dividends, Krystal Biotech isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Krystal Biotech's main competitors or similar companies to consider before investing?
When looking at Krystal Biotech, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 145.12% 200.20% Praxis Precision
PRAX9.60B Healthcare Biotechnology 501.76% 1,560.93% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.89% -31.20% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Krystal Biotech Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Krystal Biotech's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.91%, the Debt to Equity ratio from the most recent quarter is 0.77, and its Gross Profit Margin stands at 93.85%.
- What is the recent revenue and earnings growth for KRYS?
- Looking at Krystal Biotech's growth, its revenue over the trailing twelve months (TTM) was $389M. Compared to the same quarter last year (YoY), quarterly revenue grew by 17.50%, and quarterly earnings saw a YoY growth of 13.00%.
- How much of KRYS stock is held by insiders and institutions?
- Wondering who owns Krystal Biotech stock? Company insiders (like executives and directors) hold about 11.41% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.71%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.